These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 2786751

  • 1. Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate.
    Weiner LM, O'Dwyer J, Kitson J, Comis RL, Frankel AE, Bauer RJ, Konrad MS, Groves ES.
    Cancer Res; 1989 Jul 15; 49(14):4062-7. PubMed ID: 2786751
    [Abstract] [Full Text] [Related]

  • 2. Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer.
    Byers VS, Rodvien R, Grant K, Durrant LG, Hudson KH, Baldwin RW, Scannon PJ.
    Cancer Res; 1989 Nov 01; 49(21):6153-60. PubMed ID: 2790828
    [Abstract] [Full Text] [Related]

  • 3. Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration.
    Conry RM, Khazaeli MB, Saleh MN, Ghetie V, Vitetta ES, Liu T, LoBuglio AF.
    J Immunother Emphasis Tumor Immunol; 1995 Nov 01; 18(4):231-41. PubMed ID: 8680651
    [Abstract] [Full Text] [Related]

  • 4. Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies.
    Gould BJ, Borowitz MJ, Groves ES, Carter PW, Anthony D, Weiner LM, Frankel AE.
    J Natl Cancer Inst; 1989 May 10; 81(10):775-81. PubMed ID: 2785605
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
    Messmann RA, Vitetta ES, Headlee D, Senderowicz AM, Figg WD, Schindler J, Michiel DF, Creekmore S, Steinberg SM, Kohler D, Jaffe ES, Stetler-Stevenson M, Chen H, Ghetie V, Sausville EA.
    Clin Cancer Res; 2000 Apr 10; 6(4):1302-13. PubMed ID: 10778955
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics in the rat of a panel of immunotoxins made with abrin A chain, ricin A chain, gelonin, and momordin.
    Wawrzynczak EJ, Cumber AJ, Henry RV, May J, Newell DR, Parnell GD, Worrell NR, Forrester JA.
    Cancer Res; 1990 Dec 01; 50(23):7519-26. PubMed ID: 2253201
    [Abstract] [Full Text] [Related]

  • 8. Phase I immunotoxin trial in patients with B-cell lymphoma.
    Vitetta ES, Stone M, Amlot P, Fay J, May R, Till M, Newman J, Clark P, Collins R, Cunningham D.
    Cancer Res; 1991 Aug 01; 51(15):4052-8. PubMed ID: 1855219
    [Abstract] [Full Text] [Related]

  • 9. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma.
    Schnell R, Staak O, Borchmann P, Schwartz C, Matthey B, Hansen H, Schindler J, Ghetie V, Vitetta ES, Diehl V, Engert A.
    Clin Cancer Res; 2002 Jun 01; 8(6):1779-86. PubMed ID: 12060617
    [Abstract] [Full Text] [Related]

  • 10. Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma.
    LeMaistre CF, Rosen S, Frankel A, Kornfeld S, Saria E, Meneghetti C, Drajesk J, Fishwild D, Scannon P, Byers V.
    Blood; 1991 Sep 01; 78(5):1173-82. PubMed ID: 1878584
    [Abstract] [Full Text] [Related]

  • 11. A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma.
    Grossbard ML, Multani PS, Freedman AS, O'Day S, Gribben JG, Rhuda C, Neuberg D, Nadler LM.
    Clin Cancer Res; 1999 Sep 01; 5(9):2392-8. PubMed ID: 10499609
    [Abstract] [Full Text] [Related]

  • 12. Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin.
    Frankel AE, Laver JH, Willingham MC, Burns LJ, Kersey JH, Vallera DA.
    Leuk Lymphoma; 1997 Jul 01; 26(3-4):287-98. PubMed ID: 9322891
    [Abstract] [Full Text] [Related]

  • 13. Superantigen-targeted therapy: phase I escalating repeat dose trial of the fusion protein PNU-214565 in patients with advanced gastrointestinal malignancies.
    Alpaugh RK, Schultz J, McAleer C, Giantonio BJ, Persson R, Burnite M, Nielsen SE, Vitek L, Persson B, Weiner LM.
    Clin Cancer Res; 1998 Aug 01; 4(8):1903-14. PubMed ID: 9717818
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
    Shah SA, Halloran PM, Ferris CA, Levine BA, Bourret LA, Goldmacher VS, Blättler WA.
    Cancer Res; 1993 Mar 15; 53(6):1360-7. PubMed ID: 7680284
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Single-dose murine monoclonal antibody ricin A chain immunotoxin in the treatment of metastatic melanoma: a phase I trial.
    Gonzalez R, Salem P, Bunn PA, Zukiwski AA, Lamb R, Benjamin RS, Spitler L, Wedel N, Robinson WA.
    Mol Biother; 1991 Dec 15; 3(4):192-6. PubMed ID: 1768370
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. In vitro and in vivo antitumor activity of ZENECA ZD0490, a recombinant ricin A-chain immunotoxin for the treatment of colorectal cancer.
    Calvete JA, Newell DR, Wright AF, Rose MS.
    Cancer Res; 1994 Sep 01; 54(17):4684-90. PubMed ID: 8062265
    [Abstract] [Full Text] [Related]

  • 20. Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma.
    Schnell R, Vitetta E, Schindler J, Barth S, Winkler U, Borchmann P, Hansmann ML, Diehl V, Ghetie V, Engert A.
    Leuk Lymphoma; 1998 Aug 01; 30(5-6):525-37. PubMed ID: 9711915
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.